Pediatrix Medical Group (MD) Earnings Date & Reports

Key Takeaways

• Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% year over year and slightly above analyst consensus estimates.
• Adjusted earnings per share (EPS) came in at $0.72, beating consensus estimates of roughly $0.65 and rising from $0.67 in the prior-year quarter.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $85.5 million, exceeding expectations even as it declined modestly from $87.3 million a year earlier.
• Management raised its full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, up from its prior $280 million to $300 million outlook.
• Same-unit revenue grew 0.6%, supported by a favorable shift in payor mix and higher patient acuity in neonatology.
• For additional context, explore Pediatrix Medical Group's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover AI-driven trade ideas and market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

As a leading physician-services group focused on prenatal, neonatal, and pediatric care, Pediatrix Medical Group sits at the intersection of healthcare demand, reimbursement trends, and hospital relationships. Its quarterly results offer investors a read on patient volumes, payor mix, and the effectiveness of its revenue cycle management. The third quarter is particularly important because it follows a stretch of consistent earnings beats and comes as management works to improve operating efficiency while evaluating acquisitions in the women's and children's space. With shares having already climbed sharply in 2026, this report tests whether the company's margin and cash-collection momentum can justify the market's elevated expectations.

Reported Results

For the three months ended September 30, 2026, Pediatrix Medical Group reported net revenue of $501.4 million, a 1.7% increase from $492.9 million in the prior-year period. The result modestly exceeded consensus estimates of roughly $497 million. Growth reflected a 1.1% contribution from non-same-unit activity tied to recent acquisitions, partially offset by practice dispositions, plus a 0.6% increase in same-unit revenue.

On a GAAP (Generally Accepted Accounting Principles) basis, net income was $47.0 million, or $0.59 per diluted share, compared with $71.7 million, or $0.84 per share, a year earlier — a period that benefited from a $20.9 million gain on investments in divested businesses. Adjusted EPS, which excludes non-recurring items such as amortization, stock-based compensation, and restructuring costs, was $0.72, up from $0.67 in the prior-year quarter and above the consensus estimate of about $0.65.

Adjusted EBITDA was $85.5 million, compared with $87.3 million in the same quarter last year. The modest decline reflected higher expenses relative to revenue growth at existing units, partially offset by favorable contributions from recent acquisitions. Same-unit revenue from net reimbursement-related factors rose 0.3%, helped by a favorable payor mix, higher administrative fees from hospital partners, and increased patient acuity in neonatology. The percentage of services reimbursed by commercial and other non-government payors improved by 70 basis points.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, making it a useful companion for earnings-focused research and broader market analysis.

Market Reaction and Investor Sentiment

Heading into the report, investor sentiment around Pediatrix Medical Group had been notably positive, with the stock up about 35% year to date versus a roughly 13% gain for the S&P 500. Analysts had maintained a generally neutral "Hold" stance, and the third-quarter beat on both revenue and adjusted EPS, combined with the upward revision to full-year adjusted EBITDA guidance, reinforced the narrative of improving operational execution. The key drivers of investor interpretation include sustained strength in cash collections, a favorable payor mix, and continued share repurchases, which reduced the weighted average share count and supported per-share results. The main offsetting factor is the modest year-over-year decline in adjusted EBITDA, which highlights lingering cost pressures.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important signal is management's decision to raise full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, with the midpoint of $295 million sitting above consensus estimates near $289 million. This suggests the company expects its margin and reimbursement trends to remain supportive through the fourth quarter.

Investors should watch same-unit patient volume trends, particularly neonatal intensive care unit (NICU) days and hospital-based services, which have been a persistent source of softness. Reimbursement-related factors, including payor mix and administrative fees from hospital contracts, will also remain central, since these have driven much of the recent revenue growth even as volumes lag.

Cost management is another key area. Practice salaries and benefits remain the largest expense line, and any acceleration in clinical wage inflation could pressure margins. The company's continued focus on revenue cycle management (RCM) efficiency and its willingness to pursue acquisitions in adjacent women's and children's specialties will shape the growth trajectory. Finally, the balance sheet remains a source of optionality, with no borrowings under its revolving credit facility and an active share-repurchase program supporting per-share results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations